SmithKline/Coulter Bexxar
Executive Summary
FDA issues refuse-to-file letter Aug. 27. The iodine I 131 tositumomab BLA for relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma was submitted June 30. FDA requested reformatting of certain sections and additional analyses of existing data; no new clinical trial information was requested. Coulter expects a new filing in six weeks
You may also be interested in...
Lymerix Two-Month Dose Expected By Mid-2000, Pediatric Data By Year-End
SmithKline Beecham's Lymerix two-month accelerated dosing regimen could receive FDA approval in the first half of 2000, Jean-Pierre Garnier, PhD, said Sept. 16 at the Bear Stearns health care conference in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011